Siemens Healthineers Doubles Down on High-Stakes Diagnostics

Siemens Healthineers joins major Alzheimer's study and inks cancer tracer deal, pivoting to high-value diagnostics as sales in China decline and currency headwinds mount.

Siemens Healthineers is making aggressive moves in two of medicine's most challenging fields, even as significant financial pressures mount. The company has simultaneously entered a major Alzheimer's research consortium and clinched a deal to produce a novel cancer imaging agent, signaling a strategic pivot toward high-value diagnostics.

The Alzheimer's initiative involves joining the Bio-Hermes-002 study led by the Global Alzheimer's Platform Foundation. As a licensed partner alongside industry giants like Biogen, Eli Lilly, and Roche, Siemens Healthineers aims to revolutionize dementia diagnosis. The study focuses on improving the detection of amyloid and tau deposits in the brain through the analysis of blood-based and digital biomarkers.

Parallel to this, the company has signed a clinical supply agreement with Australian biopharma firm Radiopharm Theranostics. The partnership centers on RAD101, a Fluorine-18 labeled PET tracer designed to solve a critical diagnostic problem in brain metastases. With over 300,000 new cases annually in the U.S., differentiating between real tumor growth and radiation-induced tissue changes post-treatment is a major challenge. RAD101 targets fatty acid synthase (FASN) to provide a metabolic distinction, with interim Phase-2b data showing a 90% concordance rate with MRI. The FDA has granted the tracer Fast Track status.

Siemens Healthineers will leverage its established U.S. network of radiopharmacies to manufacture and distribute RAD101, a logistical necessity given the tracer's 110-minute half-life. This infrastructure provides a competitive edge in the radiopharma space.

These strategic bets are unfolding against a backdrop of considerable operational strain. The company's diagnostics segment recently contracted by 3%, primarily due to an anti-corruption campaign in China that has centralized local procurement and dampened sales. Currency fluctuations are projected to weigh on EBIT by 200 to 250 million euros this year, with the additional threat of potential U.S. tariffs posing a further 500 million euro risk.

Furthermore, a significant corporate overhaul is pending. Parent company Siemens AG plans to spin off 30% of its Siemens Healthineers stake directly to its own shareholders, which would reduce its holding to approximately 37%. A detailed timeline for this transaction remains undisclosed.

This difficult environment has hit the stock, which is down roughly 16% year-to-date, trading around 37.25 euros. Management, however, is sticking to its full-year guidance, targeting comparable revenue growth of 5-6% and an adjusted earnings per share range of 2.20 to 2.40 euros.

Upcoming investor events will be critical for reinforcing confidence. The company will present its Asia strategy at the HSBC Global Investment Summit in Hong Kong on April 14, followed by portfolio updates at the DMEA trade fair in Berlin from April 21-23. A key focus will be demonstrating stabilization in the crucial but recently weak Chinese diagnostics market.

The RAD101 partnership underscores a strategic shift toward higher-margin areas like advanced PET imaging and oncology, which reside within the company's growing Imaging segment. The upcoming quarterly report in May will reveal whether growth here can sufficiently offset diagnostics weakness and keep annual targets within reach. Final Phase-2b results for RAD101 are expected in the first half of 2026, which will determine the path to a potential Phase 3 registration study.